Lasa Supergeneri (LASA)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trading at 0.49 times book value, well below ₹17.11 book value per share.
• Low debt-to-equity of 0.13 reduces immediate insolvency risk.
• Promoter holding of 53.65% aligns promoter interests with minority shareholders.

Concerns

• Sales have collapsed by 93.35%; latest quarterly revenue is only ₹2 crore with a net loss of ₹3 crore.
• ROE of -48.74% and ROCE of -1.00% reflect severe capital destruction.
• Piotroski F-Score of 2/9 indicates very poor financial health.
• P/E of 148.07 is misleading because current operations are loss-making.

AI Analysis

At first glance, a price-to-book of 0.49 against a book value of ₹17.11 looks like a Graham cigar butt. But value investing is not simply buying low P/B; it is buying assets that earn an acceptable return. Lasa Supergeneri earns none. The latest quarter delivered only ₹2 crore in sales and a net loss of ₹3 crore. Sales have fallen by 93.35%. That is not a cyclical dip; that is franchise destruction. With ROE at -48.74% and ROCE at -1.00%, the company is destroying every rupee of equity it possesses. The Piotroski F-score of 2/9 reinforces this picture of distress. A P/E of 148.07 is worthless in this context—it comes from a tiny trailing profit while current operations are losing money. The only genuine positive is the low debt-to-equity of 0.13; the company is not at risk of imminent bankruptcy. Promoter holding of 53.65% does align incentives, but ownership concentration cannot compensate for absent customers and losses larger than revenue. At ₹8.36, the market cap is ₹40 crore against a book value of roughly ₹82 crore. That sounds tantalizing. But a book value built on pharma assets can shrink quickly when sales collapse; a business losing ₹3 crore on ₹2 crore quarterly revenue may have assets worth far less than stated. The 52-week range of ₹5.67 to ₹14.08 tells me this is a volatile, falling knife. Buffett would say it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. This is not a wonderful company. At best, it is an asset play for a patient scavenger, but only if operations stabilise and the assets prove real. Today, the evidence says wait.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer